ME [NASD]
23andMe Holding Co.
Index- P/E- EPS (ttm)-1.19 Insider Own1.00% Shs Outstand449.90M Perf Week2.45%
Market Cap1.10B Forward P/E- EPS next Y-0.73 Insider Trans-1.21% Shs Float438.46M Perf Month21.84%
Income-314.50M PEG- EPS next Q-0.19 Inst Own41.80% Short Float / Ratio5.46% / 8.98 Perf Quarter-17.16%
Sales297.60M P/S3.68 EPS this Y85.80% Inst Trans7.95% Short Interest23.94M Perf Half Y-12.54%
Book/sh1.82 P/B1.38 EPS next Y7.60% ROA-28.10% Target Price5.69 Perf Year-43.08%
Cash/sh0.94 P/C2.67 EPS next 5Y- ROE-35.40% 52W Range2.02 - 6.31 Perf YTD16.20%
Dividend- P/FCF- EPS past 5Y- ROI-27.40% 52W High-60.22% Beta-
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin46.40% 52W Low24.26% ATR0.15
Employees728 Current Ratio3.50 Sales Q/Q37.10% Oper. Margin- RSI (14)54.37 Volatility5.30% 6.44%
OptionableYes Debt/Eq0.00 EPS Q/Q-261.90% Profit Margin- Rel Volume0.59 Prev Close2.42
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume2.67M Price2.51
Recom2.20 SMA2010.33% SMA50-4.73% SMA200-14.84% Volume1,582,540 Change3.72%
Nov-29-22Initiated Berenberg Buy $7
Sep-22-22Initiated Cowen Outperform $6
Nov-15-21Downgrade Citigroup Buy → Neutral $12 → $13
Aug-17-21Initiated Credit Suisse Outperform $13
Jul-12-21Initiated Citigroup Buy $14
Jan-26-23 04:05PM
Jan-25-23 07:30AM
Jan-10-23 08:25AM
Dec-13-22 11:10AM
Dec-05-22 09:51AM
12:00AM Loading…
12:00AM
Dec-01-22 12:00PM
Nov-17-22 01:58PM
Nov-15-22 12:04PM
Nov-07-22 04:01PM
08:00AM
Oct-27-22 06:45AM
Oct-25-22 01:05PM
Oct-24-22 04:05PM
Oct-21-22 10:15AM
04:10PM Loading…
Oct-12-22 04:10PM
Oct-11-22 07:51AM
Oct-05-22 10:30AM
08:21AM
Sep-19-22 06:45AM
Sep-15-22 06:00AM
05:16AM
Sep-07-22 06:39AM
Sep-02-22 06:22AM
Aug-30-22 02:48PM
Aug-25-22 12:10PM
09:09AM
Aug-19-22 08:43AM
Aug-16-22 09:03AM
Aug-11-22 02:58PM
06:34AM Loading…
06:34AM
Aug-08-22 04:05PM
01:31PM
Aug-03-22 08:15AM
Jul-25-22 04:05PM
Jul-11-22 02:03PM
Jul-08-22 10:18AM
Jul-01-22 06:00AM
Jun-17-22 03:27PM
Jun-08-22 09:03PM
Jun-02-22 07:32AM
May-27-22 02:28PM
May-26-22 06:51PM
04:05PM
11:13AM
May-24-22 06:30AM
May-12-22 04:10PM
May-03-22 03:04PM
Apr-29-22 03:35PM
Apr-10-22 06:00AM
Apr-06-22 06:11PM
10:19AM
Mar-31-22 06:33AM
Mar-24-22 06:50AM
Mar-15-22 06:45AM
Feb-28-22 02:19PM
Feb-25-22 08:30AM
Feb-24-22 10:41AM
Feb-17-22 09:00AM
Feb-16-22 08:52AM
Feb-15-22 11:30AM
Feb-14-22 03:30PM
Feb-10-22 04:04PM
Feb-03-22 11:49AM
Jan-27-22 04:05PM
Jan-24-22 09:38AM
Jan-18-22 05:23PM
06:55AM
Jan-10-22 08:00AM
Jan-07-22 10:50AM
Jan-06-22 09:00AM
Jan-03-22 08:00AM
Dec-28-21 04:05PM
Dec-21-21 07:12AM
Dec-16-21 06:21AM
Dec-15-21 09:08PM
Dec-13-21 07:15AM
Dec-10-21 06:25AM
Dec-03-21 02:21PM
Dec-02-21 10:46AM
Nov-30-21 09:15AM
Nov-24-21 06:20AM
Nov-22-21 04:15PM
Nov-15-21 12:52PM
Nov-11-21 01:22PM
04:50AM
Nov-10-21 04:05PM
Nov-09-21 04:30PM
12:04PM
09:00AM
Nov-03-21 04:30PM
Nov-02-21 03:48PM
Nov-01-21 04:05PM
Oct-29-21 08:29AM
Oct-26-21 06:18PM
Oct-22-21 03:48PM
11:42AM
10:23AM
07:36AM
07:32AM
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HIBBS KATHY LChief Administrative OfficerDec 05Sale3.2526,25985,342235,829Dec 06 05:44 PM
SCHELLER RICHARD HDirectorNov 11Sale3.2418,42159,68472,388Nov 14 04:38 PM
Hillan Kenneth J.Chief Therapeutics OfficerAug 24Sale3.648,75331,861196,083Aug 25 05:00 PM
Lovell EvanDirectorMar 10Buy4.4111,46750,55811,467Mar 11 04:05 PM